NYXOAH S.A.

Nyxoah opens the books for the quarter ended 30.06.2026; six analysts expect an EPS of -0.387 EUR versus -0.550 EUR a year earlier. Revenues for the past quarter are forecast at about 7.6 million EUR, an increase of 464% from 1.3 million EUR a year ago. For the current fiscal year the consensus estimates (nine analysts) are a loss of -1.176 EUR per share and revenues of around 37.3 million EUR versus 10.0 million EUR in the prior year. » More on finanzen.net

Nyxoah has completed an equity financing of $95 million and expects a second tranche of $15 million from an EIB loan by the end of June, bringing the total to $110 million. The funds are intended to support the commercial ramp-up of the Genio system for treating obstructive sleep apnea in the US. The stock is trading near its 52-week low at $1.31; analysts see potential undervaluation, but the company warns of rapid cash burn. » More on de.investing.com

Nyxoah has received financing commitments of up to $77 million, consisting of a private placement of €22 million, a registered direct placement of $5.6 million and convertible notes of up to €45 million. Investors include Cochlear, Resmed and company insiders; the proceeds are intended to fund US commercialization after expected FDA approval, international launches, clinical data collection and R&D for system upgrades. The company reports low revenues (about $5.81 million annually), maintains analysts’ buy recommendations and has filed a patent lawsuit against Inspire. » More on de.investing.com